Meeting
2014 ASCO Annual Meeting
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients with induced immune responses and a prolonged OS.
Authors
Yoshihiro Yoshitake
Department of Oral & Maxillofacial Surgery,Graduate School of Medical Sciences, Kumamoto University, Kumamoto City, Japan
Yoshihiro Yoshitake , Daiki Fukuma , Akira Yuno , Masatoshi Hirayama , Hideki Nakayama , Takuya Tanaka , Masashi Nagata , Kenta Kawahara , Yoshihiro Nakagawa , Ryoji Yoshida , Hidenao Ogi , Akimitsu Hiraki , Hirofumi Jono , Akinobu Hamada , Koji Yoshida , Takuya Tsunoda , Yasuharu Nishimura , Yusuke Nakamura , Masanori Shinohara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Vaccines
Clinical Trial Registration Number
000008379
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3094)
DOI
10.1200/jco.2014.32.15_suppl.3094
Abstract #
3094
Poster Bd #
161
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Cancer genomics-based approach for development of new immunotherapeutics for lung cancers.
First Author: Yataro Daigo
Poster
2021 Genitourinary Cancers Symposium
Phase II open-label study of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced or metastatic urothelial carcinoma.
First Author: Syed A. Hussain
Poster
2016 ASCO Annual Meeting
Randomized phase II study of WT1 peptide vaccine plus gemcitabine for advanced pancreatic ductal adenocarcinoma (PDAC): Clinical efficacy and immune response.
First Author: Sumiyuki Nishida
Poster
2015 ASCO Annual Meeting
Phase 2 studies of multiple peptides cocktail vaccine for treatment-resistant cervical and ovarian cancer.
First Author: Satoshi Takeuchi